Key clinical point: High PD-L1 expression was associated with a clinically meaningful improvement in OS in patients treated with atezolizumab + chemotherapy vs. chemotherapy alone.
Major finding: Median OS in patients with high PD-L1 expression treated with atezolizumab + chemotherapy vs. chemotherapy alone was 23.4 vs. 10.2 months; HR, 0.48.
Study details: The randomized phase 3 IMpower131 study of 1,021 patients.
Disclosures: Dr. Cappuzzo reported having no disclosures.
Cappuzzo F et al. WCLC 2019,.